{"filing":{"accession_number":"0001213900-26-075499","cik":"0001954594","ticker":"HAO","company_name":"Haoxi Health Technology Ltd","form":"6-K","filing_date":"2026-07-06","report_date":null,"primary_document":"ea0297119-6k_haoxi.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1954594/000121390026075499/ea0297119-6k_haoxi.htm"},"events":[{"id":16217,"run_id":14471,"accession_number":"0001213900-26-075499","anchor_item_number":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The 6-K discloses results of an extraordinary general meeting held on July 6, 2026, where shareholders voted on three proposals: (1) a special resolution to reduce and reorganize the Company's authorized share capital from US$35.2 trillion to US$11 million with a dramatic reduction in par value per share from US$0.32 to US$0.0000001, (2) adoption of amended memorandum and articles of association to reflect the capital reduction, and (3) an adjournment proposal. All three proposals were approved with voting tallies provided. This is a classic shareholder_vote_results disclosure under Item 5.07 equivalent, and the capital restructuring is material to investors as it fundamentally alters the share structure and capitalization.","company_name":"Haoxi Health Technology Ltd","ticker":"HAO","filing_date":"2026-07-06","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":14257,"accession_number":"0001213900-26-075499","item_number":null,"item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The 6-K discloses results of an extraordinary general meeting held on July 6, 2026, where shareholders voted on three proposals: (1) a special resolution to reduce and reorganize the Company's authorized share capital from US$35.2 trillion to US$11 million with a dramatic reduction in par value per share from US$0.32 to US$0.0000001, (2) adoption of amended memorandum and articles of association to reflect the capital reduction, and (3) an adjournment proposal. All three proposals were approved with voting tallies provided. This is a classic shareholder_vote_results disclosure under Item 5.07 equivalent, and the capital restructuring is material to investors as it fundamentally alters the share structure and capitalization.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-07T18:53:37.884373+00:00","company_name":"Haoxi Health Technology Ltd","ticker":"HAO","filing_date":"2026-07-06"}]}